PUBLIC COMPANY
save$DYNDyne Therapeutics, Inc.
$DYN16.34+1.93%Waltham, MA, USupdated 9h ago
community read0 votes
pipeline
4
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
2Preclinical2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
- phase3Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
- phase2Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 22, 26SELLRhodes Jason P· −$2.97M↗
- Apr 22, 26SELLRhodes Jason P· −$1.49M↗
- Apr 22, 26SELLRhodes Jason P· −$1.17M↗
- Apr 22, 26SELLKersten Dirk· director−$53K↗
- Apr 22, 26SELLRhodes Jason P· −$29K↗
- Apr 21, 26SELLRhodes Jason P· −$2.78M↗
- Apr 21, 26SELLRhodes Jason P· −$1.39M↗
- Apr 21, 26SELLRhodes Jason P· −$1.10M↗
- Apr 21, 26SELLKersten Dirk· director−$166K↗
- Apr 21, 26SELLRhodes Jason P· −$31K↗
- Apr 21, 26SELLRhodes Jason P· −$27K↗
- Apr 21, 26SELLRhodes Jason P· −$15K↗
- Apr 21, 26SELLRhodes Jason P· −$12K↗
- Apr 21, 26SELLRhodes Jason P· −$301↗
- Apr 20, 26SELLRhodes Jason P· −$2.86M↗
- Apr 20, 26SELLKersten Dirk· director−$2.51M↗
- Apr 20, 26SELLRhodes Jason P· −$1.44M↗
- Apr 20, 26SELLRhodes Jason P· −$1.13M↗
- Apr 20, 26SELLRhodes Jason P· −$28K↗
- Apr 17, 26SELLKersten Dirk· director−$4.30M↗
🐶 Hiring Signal
News
- Biopharma hiring hotspots: States, disciplines where demand is highestAs biopharma job openings rose this year, opportunities were greatest in Massachusetts and California and in the science/R&D and clinical disciplines, according to BioSpace data. Several other loca…biospace · 12d ago
- Novartis RNA drug falls short in rare muscle disease studyThe failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.biopharma_dive · 21d ago
- Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappointsWhile Novartis’ antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity…biospace · 21d ago
- Capricor CEO won’t rule out legal action against FDA after negative adcommAfter an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior mot…biospace · 2mo ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 3mo ago
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that